Rigel licenses VEPPANU breast cancer drug for $85 million upfront
Go back to Rigel licenses VEPPANU breast cancer drug for $85 million upfront| Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) | Delayed: 32.91 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $32.91 | 52 Week High | $4.38 | |||
| Open | $32.91 | 52 Week Low | $1.88 | |||
| Day High | $32.91 | P/E | N/A | |||
| Day Low | $32.91 | EPS | $-1.12 | |||
| Volume | 49 | |||||
